MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™

Next-generation bone graft, powered by NanoLift^™ Surface Technology, supports bone regeneration following surgery

EDISON, N.J. & SALT LAKE CITY--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of orthobiologic solutions, today announced the launch of Summit Matrix™, an advanced synthetic bone graft designed to improve bone regeneration after orthopedic and spinal surgeries. Powered by NanoLift™ surface technology, Summit Matrix combines nanoscale topography, biomimetic chemistry, and exceptional handling to enhance the surgeon experience.

“MTF Biologics was founded by orthopedic surgeons nearly 40 years ago with a focus on providing solutions that improve patient care,” said Brad Bailey, Vice President and General Manager of MTF Biologics’ Orthopedic Franchise. “Summit Matrix continues this legacy, representing a significant leap forward in bone graft technology. We are pleased to grow our partnership with Kolosis BIO with this innovation. Together, our organizations are delivering innovative solutions that enhance surgical efficiency and clinical practice.”

Summit Matrix marks a significant advancement in the MTF Biologics and Kolosis offering of osteobiologic solutions, integrating seamlessly with tissues including Kore Fiber^®, Prime HD^®, and DBX^® Mix and DBX^® Putty. Summit Matrix features NanoLift’s nanocrystalline, plate-like surface, which supports cell activity to promote bone formation. Its hydroxycarbanoapatite composition closely mimics natural bone mineral, enabling optimal resorption and osseointegration.

“Kolosis has emerged as the leading pure-play orthobiologics provider in spine and orthopedics, and we’re thrilled to add Summit Matrix to our expanding portfolio,” said Collin Begley, CEO of Kolosis BIO. “This technology will be a formidable contender in the market immediately, and with MTF Biologics’ collaboration, we will be able to offer a best-in-class portfolio of allograft tissues and synthetic ceramics, all through one trusted partner.”

About MTF Biologics

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. In partnership with organ and tissue recovery organizations, MTF Biologics provides exceptional services, resources, and expertise to donors and their families; tissue and organ transplant patients; and clinicians and scientists who advance patient care. The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe.

About Kolosis BIO

Kolosis BIO is a rising biologics pure-play, dedicated to commercializing cutting-edge technologies to multiple verticals in the surgical biologics space. With a proven track record of scaling market-leading technologies, Kolosis is dedicated to driving innovation and pushing the boundaries of science to enhance patient outcomes. With a focus on providing bold technologies and relentless execution, Kolosis has become a leading force in the surgical biologics market. For more information, please visit www.kolosis.com.